跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Why AI-Designed Drugs Haven't Changed Medicine Yet

1The Promise and the Puzzle2From Molecule to Medicine: The Journey a Drug Must Survive3Where AI Actually Helps in the Pipeline4The Prediction Gap: When a Good Molecule Meets a Real Body5The Long, Expensive Road of Clinical Trials6Money, Incentives, and the Business of Drug Development7Regulation, Evidence, and Trust8What Would Have to Change
Money, Incentives, and the Business of Drug Development

Why patents are the engine, not the reward

3 / 4
The thing to hold onto is the order of events. Patents and exclusivity are not a reward handed out after a drug succeeds; they are the reason the money is risked in the first place. Without a window of exclusive pricing, a competitor could copy the winner immediately, the expected return would collapse, and no one would fund the many failures that produce one success. That also explains why development clusters around conditions that can support high prices, even when the medical need lies elsewhere.
0:00 / 0:00

Protection comes before the spending, not after

The exclusivity window is what allows a company to price a successful drug high enough to cover the cost of its failures. Remove it and the expected return collapses, so the funding never happens in the first place.

A consequence worth noticing

Because the incentive depends on price, diseases with large, wealthy markets attract more development than diseases with greater need but less ability to pay. This is a structural feature of the system, not a moral failing of any one company.

上一页3 / 4下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion